Pfizer raises 2026 outlook to $62B-$64B revenue and $2.95-$3.05 adjusted EPS
FROM THE WIRE · SEEKINGALPHA.COM
Earnings Call Insights: Pfizer (PFE) Q3 2026 MANAGEMENT VIEW * "I'm pleased with another strong quarter for Pfizer." (Chairman & CEO Albert Bourla) "Our excellent commercial execution, including 32% operational revenue growth in the quarter for our launch and acquired products…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishA mega-cap raising full-year revenue and earnings guidance is a significant signal for the pharma sector and the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third quarter 2026 revenue was $16.6 billion, ahead of management expectations.
- 02Adjusted diluted EPS was $0.87, exceeding expectations and including a $0.10 charge tied to the Innovent transaction.
- 03Operational revenue growth was 32% in the quarter for launch and acquired products.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets